John Brady

Royal Brisbane and Women's Hospital — Australia

Immunology and Microbiology · Life Sciences

70h-index18.0kcitations346works2.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

T-cell and Retrovirus Studies(87), Animal Disease Management and Epidemiology(67), Vector-Borne Animal Diseases(59), Ovarian cancer diagnosis and treatment(41), Insect behavior and control techniques(37)

Publications346 total

THE ANSWER IS ALWAYS SARCOID
CHEST Journal·2025
BRONCHIECTASIS: IS IT IDIOPATHIC OR IS IT HIDING IN THE GENES?
CHEST Journal·2025Open Access
2388P Results from the phase Ib dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC): The theraPb trial
Annals of Oncology·2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
The Lancet Oncology·2025· 12 cited
Phase Ib/IIa dose escalation and expansion study of [ <sup>212</sup> Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II study.
Journal of Clinical Oncology·2025· 1 cited
Extragonadal teratoma in a fallopian tube; a common entity in an uncommon location
Pathology·2024Open Access
Data from Expression Profiling of Mucinous Tumors of the Ovary Identifies Genes of Clinicopathologic Importance
2023Open Access
Supplementary Gene List from Expression Profiling of Mucinous Tumors of the Ovary Identifies Genes of Clinicopathologic Importance
2023Open Access
Supplementary Gene List from Expression Profiling of Mucinous Tumors of the Ovary Identifies Genes of Clinicopathologic Importance
2023Open Access
Data from Expression Profiling of Mucinous Tumors of the Ovary Identifies Genes of Clinicopathologic Importance
2023Open Access
Supplementary Table 4 from A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer
2023Open Access
Supplementary Figure 3 from A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer
2023Open Access
Supplementary Table 3 from A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer
2023Open Access
Supplementary Table 4 from A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer
2023Open Access
Supplementary Table 1 from A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer
2023Open Access
Data from Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary
2023Open Access
Supplementary Figure Legends 1-4 from A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer
2023Open Access
Supplementary Table 2 from A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer
2023Open Access
Supplementary Figure 2 from A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer
2023Open Access
Supplementary Figure 5 from A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer
2023Open Access
page 1 of 18Next →

Frequent Co-authors

Michael F. Radonovich(15), Cynthia A. Pise-Masison(12), Fatah Kashanchi(9), Tomás Bonome(5), Michael J. Birrer(5), Janet F. Duvall(4), Cindy A. Pise-Masison(3), Timothy P. Reilly(3), Mohammed Bourdi(3), John W. George(3), Lance R. Pohl(3), Samuel C. Mok(3), Howard Donninger(3), Renaud Mahieux(3), Gabriella Gibson(3), Meisheng Zhou(2), Panu E. Kovanen(2), Warren J. Leonard(2), Barbara Ensoli(2), Joanna H. Shih(2)